C‑Myc inhibitor 10058‑F4 increases the efficacy of dexamethasone on acute lymphoblastic leukaemia cells

Lv,Mei; Wang,Yi; Wu,Wenmiao; Yang,Shujun; Zhu,Huiling; Hu,Bei; Chen,Ying; Shi,Cong; Zhang,Yi; Mu,Qitian; Ouyang,Guifang

doi:10.3892/mmr.2018.8935

C‑Myc inhibitor 10058‑F4 increases the efficacy of dexamethasone on acute lymphoblastic leukaemia cells

Authors:
- Mei Lv
- Yi Wang
- Wenmiao Wu
- Shujun Yang
- Huiling Zhu
- Bei Hu
- Ying Chen
- Cong Shi
- Yi Zhang
- Qitian Mu
- Guifang Ouyang
View Affiliations

Affiliations: Department of Hematology, Ningbo First Hospital, Ningbo, Zhejiang 315010, P.R. China
Published online on: April 27, 2018 https://doi.org/10.3892/mmr.2018.8935
Pages: 421-428

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The long‑term survival rate in paediatric acute lymphoblastic leukaemia (ALL) exceeds 80%; however, the outcome of adult ALL remains to be poor. Glucocorticoids (GCs) are the preferred drugs in the traditional treatment of ALL patients. In the anti‑leukaemia molecular mechanisms of GCs, c‑Myc inhibition serves a critical role. In the present study, a c‑Myc inhibitor that increased the sensitivity to GCs in NALM6 cells of the B‑cell‑ALL cell line and CEM cells of the T‑cell‑ALL cell line was investigated. The data demonstrated that 10058‑F4, a c‑Myc inhibitor, increased the growth inhibition, G0/G1 phase arrest and apoptosis of the NALM6 and CEM cells as induced by dexamethasone (DXM), a type of GC. Additionally, 10058‑F4 reinforced the decreased expressions of c‑Myc, cyclin‑dependent kinase (CDK)‑4 and CDK6 in the NALM6 and CEM cells treated with DXM. These findings indicated that DXM in combination with the c‑Myc inhibitor 10058‑F4 may be a novel, potent therapeutic strategy for the treatment of ALL.

View Figures

View References

1	Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, Burnett AK, Chopra R, Wiernik PH, Foroni L, et al: In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 111:1827–1833. 2008. View Article : Google Scholar : PubMed/NCBI
2	Pui CH, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC, Rubnitz JE, Razzouk BI, Howard SC, Hudson MM, et al: Improved outcome for children with acute lymphoblastic leukemia: Results of total therapy study XIIIB at St Jude children's research hospital. Blood. 104:2690–2696. 2004. View Article : Google Scholar : PubMed/NCBI
3	Bassan R: Evolving strategies for the management of high-risk adult acute lymphoblastic leukemia. Haematologica. 90:12992005.PubMed/NCBI
4	Frey NV and Porter DL: CAR T-cells merge into the fast lane of cancer care. Am J Hematol. 91:146–150. 2016. View Article : Google Scholar : PubMed/NCBI
5	Park JH, Geyer MB and Brentjens RJ: CD19-targeted CAR T-cell therapeutics for hematologic malignancies: Interpreting clinical outcomes to date. Blood. 127:3312–3320. 2016. View Article : Google Scholar : PubMed/NCBI
6	Schreiber-Agus N and DePinho RA: Repression by the Mad(Mxi1)-Sin3 complex. Bioessays. 20:808–818. 1998. View Article : Google Scholar : PubMed/NCBI
7	Zhou F, Medh RD and Thompson EB: Glucocorticoid mediated transcriptional repression of c-myc in apoptotic human leukemic CEM cells. J Steroid Biochem Mol Biol. 73:195–202. 2000. View Article : Google Scholar : PubMed/NCBI
8	Ge Z, Guo X, Li J, Hartman M, Kawasawa YI, Dovat S and Song C: Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemia. Oncotarget. 6:42300–42311. 2015. View Article : Google Scholar : PubMed/NCBI
9	Roderick JE, Tesell J, Shultz LD, Brehm MA, Greiner DL, Harris MH, Silverman LB, Sallan SE, Gutierrez A, Look AT, et al: c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood. 123:1040–1050. 2014. View Article : Google Scholar : PubMed/NCBI
10	Gaynon PS and Carrel AL: Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia. Adv Exp Med Biol. 457:593–605. 1999. View Article : Google Scholar : PubMed/NCBI
11	Distelhorst CW: Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ. 9:6–19. 2002. View Article : Google Scholar : PubMed/NCBI
12	Tissing WJ, Meijerink JP, den Boer ML and Pieters R: Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia. 17:17–25. 2003. View Article : Google Scholar : PubMed/NCBI
13	Saffar AS, Ashdown H and Gounni AS: The molecular mechanisms of glucocorticoids-mediated neutrophil survival. Curr Drug Targets. 12:556–562. 2011. View Article : Google Scholar : PubMed/NCBI
14	Thulasi R, Harbour DV and Thompson EB: Suppression of c-myc is a critical step in glucocorticoid-induced human leukemic cell lysis. J Biol Chem. 268:18306–18312. 1993.PubMed/NCBI
15	Helmberg A, Auphan N, Caelles C and Karin M: Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor. EMBO J. 14:452–460. 1995.PubMed/NCBI
16	Mu Q, Ma Q, Lu S, Zhang T, Yu M, Huang X, Chen J and Jin J: 10058-F4, a c-Myc inhibitor, markedly increases valproic acid-induced cell death in Jurkat and CCRF-CEM T-lymphoblastic leukemia cells. Oncol Lett. 8:1355–1359. 2014. View Article : Google Scholar : PubMed/NCBI
17	Huang MJ, Cheng YC, Liu CR, Lin S and Liu HE: A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol. 34:1480–1489. 2006. View Article : Google Scholar : PubMed/NCBI
18	Holien T, Våtsveen TK, Hella H, Rampa C, Brede G, Groseth LA, Rekvig M, Borset M, Standal T, Waage A and Sundan A: Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC. Leukemia. 26:1073–1080. 2012. View Article : Google Scholar : PubMed/NCBI
19	Luscher B and Larsson LG: The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: Function and regulation. Oncogene. 18:2955–2966. 1999. View Article : Google Scholar : PubMed/NCBI
20	Weng AP, Ferrando AA, Lee W, Morris JP IV, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT and Aster JC: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 306:269–271. 2004. View Article : Google Scholar : PubMed/NCBI
21	O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, Hardwick J, Welcker M, Meijerink JP, Pieters R, et al: FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 204:1813–1824. 2007. View Article : Google Scholar : PubMed/NCBI
22	Yin X, Giap C, Lazo JS and Prochownik EV: Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene. 22:6151–6159. 2003. View Article : Google Scholar : PubMed/NCBI
23	Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE and Weinstock DM: BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 120:2843–2852. 2012. View Article : Google Scholar : PubMed/NCBI
24	Mateyak MK, Obaya AJ and Sedivy JM: c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol. 19:4672–4683. 1999. View Article : Google Scholar : PubMed/NCBI
25	Hermeking H, Rago C, Schuhmacher M, Li Q, Barrett JF, Obaya AJ, O'Connell BC, Mateyak MK, Tam W, Kohlhuber F, et al: Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci USA. 97:2229–2234. 2000. View Article : Google Scholar : PubMed/NCBI
26	Pikman Y, Alexe G, Roti G, Conway AS, Furman A, Lee ES, Place AE, Kim S, Saran C, Modiste R, et al: Synergistic drug combinations with a CDK4/6 inhibitor in T-cell acute lymphoblastic leukemia. Clin Cancer Res. 23:1012–1024. 2017. View Article : Google Scholar : PubMed/NCBI
27	Liu Y, Ge J, Li Q, Guo X, Gu L, Ma ZG, Li XH and Zhu YP: Low-dose anisomycin sensitizes glucocorticoid-resistant T-acute lymphoblastic leukemia CEM-C1 cells to dexamethasone-induced apoptosis through activation of glucocorticoid receptor and p38-MAPK/JNK. Leuk Lymphoma. 55:2179–2188. 2014. View Article : Google Scholar : PubMed/NCBI
28	Samon JB, Castillo-Martin M, Hadler M, Ambesi-Impiobato A, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Jakubczak J, Randolph S, et al: Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther. 11:1565–1575. 2012. View Article : Google Scholar : PubMed/NCBI
29	Prochownik EV and Vogt PK: Therapeutic targeting of Myc. Genes Cancer. 1:650–659. 2010. View Article : Google Scholar : PubMed/NCBI
30	Guo J, Parise RA, Joseph E, Egorin MJ, Lazo JS, Prochownik EV and Eiseman JL: Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol. 63:615–625. 2009. View Article : Google Scholar : PubMed/NCBI
31	Soodgupta D, Pan D, Cui G, Senpan A, Yang X, Lu L, Weilbaecher KN, Prochownik EV, Lanza GM and Tomasson MH: Small molecule MYC inhibitor conjugated to integrin-targeted nanoparticles extends survival in a mouse model of disseminated multiple myeloma. Mol Cancer Ther. 14:1286–1294. 2015. View Article : Google Scholar : PubMed/NCBI
32	Abraham SA, Hopcroft LE, Carrick E, Drotar ME, Dunn K, Williamson AJ, Korfi K, Baquero P, Park LE, Scott MT, et al: Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature. 534:341–346. 2016. View Article : Google Scholar : PubMed/NCBI